# HERON-Lung01: HCP commentary report

> 30 verified statements (10 from clinicians verified by NPI or staff page) from 10 commentary sources · 7 findings · updated Oct 28, 2026

## Report

- Trial: A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy
- NCT ID: NCT06671379
- Registry: https://clinicaltrials.gov/study/NCT06671379
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Phase: Phase 3
- Status: Active, not recruiting
- Indications: Non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-28
- Last checked: 2026-10-28
- Release hash: 101c855017560d630f428eaa4650b7df5a80b9126a313f7a32e718b772d66901

## Counts

- HCP commentary sources screened: 19
- Sources cited by verified statements: 12
- Verified statements: 30
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 10
- Findings: 7
- People found in screened sources: 9
- People identity-verified: 8
- Voices cited: 9

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

HERON-Lung01 asks whether SHR-A2009 improves outcomes compared with platinum chemotherapy in advanced EGFR-mutated non-small cell lung cancer after EGFR-TKI failure. Clinicians in the sources reviewed for this edition differ on whether it is ready for standard-of-care use. Efficacy attracts enthusiasm, while tolerability remains under scrutiny in their commentary. Patient selection, treatment sequencing and applicability outside China remain open questions for positioning the treatment.

## Open Medical Affairs question

What survival maturity, day-to-day toxicity, patient-selection evidence and access conditions would justify adoption in this post-TKI population?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Promising efficacy has not produced agreement on readiness for standard-of-care use
- F2. Similar severe-event rates do not settle the tolerability question
- F3. Patient selection remains unresolved, with a distinct MET-testing alternative raised in the discussion
- F4. More active options have increased sequencing uncertainty rather than established a preferred option
- F5. Global applicability is an explicit concern with a stated population rationale
- F6. Intracranial activity is presented as promising but still requiring subgroup evaluation
- F7. Access and first-to-market expectations remain separate from clinical readiness

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 7 | 5 | 5 | 5 | recorded | 2 |
| F2 | 8 | 7 | 7 | 6 | recorded | 3 |
| F3 | 4 | 4 | 3 | 4 | none recorded | 3 |
| F4 | 5 | 4 | 4 | 4 | none recorded | 3 |
| F5 | 4 | 2 | 2 | 2 | none recorded | 2 |
| F6 | 1 | 1 | 1 | 1 | none recorded | 2 |
| F7 | 5 | 3 | 3 | 2 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 4 | 0 | 0 | 0 | 3 | 8 | 0 | 5 posts and articles | yes |
| F2 | 1 | 0 | 0 | 3 | 4 | 8 | 0 | 6 posts and articles, 1 publication | yes |
| F3 | 3 | 0 | 0 | 0 | 1 | 4 | 1 | 3 posts and articles | yes |
| F4 | 1 | 2 | 0 | 1 | 1 | 6 | 1 | 4 posts and articles | yes |
| F5 | 2 | 1 | 0 | 0 | 1 | 5 | 1 | 2 posts and articles | yes |
| F6 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 post or article | yes |
| F7 | 3 | 0 | 0 | 0 | 2 | 5 | 0 | 3 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Progression-free survival (PFS) assessed by BICR according to RECIST v1.1: F1 (5 shared claims), F2 (3 shared claims), F3 (1 shared claims), F4 (1 shared claims), F5 (1 shared claims)
- Secondary endpoints: F1 (5 shared claims), F2 (3 shared claims), F5 (1 shared claims)
- Population and setting: F1 (1 shared claims), F2 (1 shared claims), F5 (3 shared claims), F6 (1 shared claims)
- The comparison: F1 (4 shared claims), F2 (4 shared claims), F3 (1 shared claims), F4 (1 shared claims), F5 (1 shared claims)
- Safety and tolerability: F1 (3 shared claims), F2 (7 shared claims), F5 (1 shared claims)
- Design and conduct: F1 (4 shared claims), F2 (3 shared claims), F3 (1 shared claims), F4 (1 shared claims), F5 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. Similar severe-event rates do not settle the tolerability question

An X-thread post asks about tolerability differences between ruzaltatug rezetecan and izabren.

Source: X thread, 2026-10-26.

### F5. Global applicability is an explicit concern with a stated population rationale

An X-thread account addresses the question of applicability outside China in a discussion covering PANKU-Lung01 and HERON-Lung01.

Source: X thread, 2026-10-26.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 30 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 12 | Counts free |
| Speaker attribution for cited voices | 9 | Paid |

## Trial aspects

12 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-free survival (PFS) assessed by BICR according to RECIST v1.1 | discussed | 7 | 7 |
| Secondary endpoints | discussed | 6 | 6 |
| Population and setting | discussed | 5 | 3 |
| The comparison | discussed | 7 | 6 |
| Safety and tolerability | discussed | 7 | 6 |
| Design and conduct | discussed | 6 | 6 |
| Readiness for standard-of-care adoption | discussed | 3 | 2 |
| Predictive selection and resistance-directed testing | discussed | 4 | 3 |
| Competing options, combinations and treatment sequence | discussed | 6 | 4 |
| Applicability outside China | discussed | 4 | 2 |
| Intracranial activity and brain-metastasis evaluation | discussed | 1 | 1 |
| Development rationale, access and market expectations | discussed | 5 | 3 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 19 | 10 |
| Publications (primary source, cited for context) | not screened | 1 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2026-03-20 to 2026-10-27
- Cited window: 2026-03-20 to 2026-10-27
- Retrieved: 2026-10-28

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy
- Registry: NCT06671379 (https://clinicaltrials.gov/study/NCT06671379)
- Study IDs: SHR-A2009-301
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Active, not recruiting
- Enrollment: 498 (actual)
- Start: 2024-11-29 (actual)
- Primary completion: 2026-12 (estimated)
- Primary endpoint: Progression-free survival (PFS) assessed by BICR according to RECIST v1.1 (Up to approximately 32 months)
- Intervention: SHR-A2009 monotherapy (drug)
- Intervention: platinum-based dual-agent chemotherapy (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 15 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition do not represent all HCP discussion. Comments without the trial identifier or recognizable names may be missing, and some available passages were not fully assessed for clinician views.
- Several authors relay the same presentation or a discussion covering two trials. Separate posts and reposts should not be counted as independent clinical agreement.
- OS remains immature in the commentary. The favorable trend was explicitly described as nonsignificant in a presentation account relayed by a speaker; an established survival benefit should not be inferred.
- Cross-trial comparisons do not establish which ADC is more effective or better tolerated.
- The CNS and detailed HER3 biomarker interpretations cover PANKU-Lung01 and HERON-Lung01 together; they cannot automatically be assigned to HERON-Lung01 alone.
- The HERON-Lung01 lower-grade adverse-event wording does not define an exact grade range. The publication's treatment-related attribution of the death is possible, not definite.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- A full protocol and matching regulatory labels for the compared treatments were not included. A filing, potential launch date or first-to-market expectation does not establish approval, availability or prescribing conditions.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-28: current edition, corrected 2026-10-28
  - Correction 2026-10-28: The trial is named HERON-Lung01, as its sources and the report name it (was SHR-A2009-301)
  - Correction 2026-10-28: Corrected to match the delivered report: 12 sources cited (was 10); source breakdowns; the sample findings.

Last checked for new commentary 2026-10-28. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (30 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (8 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/heron-lung01-nct06671379
- Agents: POST https://www.erudio.com/api/orders with {"report": "heron-lung01-nct06671379", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=heron-lung01-06671379

## Cite

Erudio Health. HERON-Lung01 (NCT06671379): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 28, 2026. https://www.erudio.com/reports/heron-lung01-nct06671379

## Machine access

- JSON: https://www.erudio.com/reports/heron-lung01-nct06671379.json
- Markdown: https://www.erudio.com/reports/heron-lung01-nct06671379.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "heron-lung01-06671379"}`